Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IO-R-CVP versus Gem-R-CVP for first-line diffuse large B-cell lymphoma in patients unfit for anthracyclines
2012-001900-39Phase 2Unknown
- Sponsor
- University College London
- Start
- Sep 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of inotuzumab ozogamicin, gemcitabine, rituximab, cyclophosphamide, vincristine in diffuse large B-cell lymphoma (DLBCL), sponsored by University College London. Status: unknown.
02
Drugs
inotuzumab ozogamicingemcitabinerituximabcyclophosphamidevincristine
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2012-001900-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001900-39.